Tafasitamab combo approved in Japan for relapsed, refractory DLBCL
The clinical approval was based on data from the international phase 2 L-MIND trial and the domestic phase 1b/2 J-MIND trial in Japan.
Lymphoma
Aggressive B-Cell Lymphomas
News
Myeloproliferative Neoplasms
Polycythemia Vera
Taiwan regulatory body approves ropeginterferon alfa-2b-njft in ET
Taiwan’s Ministry of Health and Welfare has approved ropeginterferon alfa-2b-njft (BESREMi) for adult patients with essential thrombocythemia, according to PharmaEssentia, the manufacturer of
Multiple Myeloma
News
CHMP recommends approval of isatuximab subcutaneous formulation for MM
The recommendation was based on results from the phase 3 IRAKLIA trial, which demonstrated that the subcutaneous formulation was noninferior to intravenous administration
AACR 2026
Acute Myeloid Leukemia
Myelodysplastic Syndromes
News
Video Interviews
John DiPersio, MD, PhD, on the future of blood cancers
In this SOHO Insider interview from the 2026 AACR Annual Meeting, John DiPersio, MD, PhD, president of the Society of Hematologic Oncology, shares
Multiple Myeloma
News
Singapore’s HSA approves NDA for CAR-T therapy eque-cel in relapsed or refractory myeloma
Eque-cel, an anti-BCMA CAR-T, has been approved in China for treating patients with relapsed or refractory myeloma who have progressed after at least
SOHO 2026
Trending now
Meetings / Conferences
News
Society Updates
Grab your SOHO t-shirts during SOHO 2026!
Your contributions fund vital programs that accelerate progress in hematologic malignancies. Visit soho.click/donate to join the initiative.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
AACR 2026
Acute Lymphoblastic Leukemia
News
Video Interviews
Nicholas Pannunzio, PhD, discusses Ph-like ALL and CRLF2 rearrangement
Nicholas R. Pannunzio, PhD, of the Chao Family Comprehensive Cancer Center, discusses the underlying etiology of CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Lymphoma
Aggressive B-Cell Lymphomas
News
FDA accepts sBLA for mosunetuzumab and polatuzumab vedotin combo in relapsed or refractory large B-cell lymphoma
The submission is supported by findings from the phase III SUNMO trial evaluating the subcutaneous formulation of mosunetuzumab alongside intravenous polatuzumab vedotin for
Multiple Myeloma
News
China NMPA approves supplemental application for generic denosumab
Developed by Mabwell's wholly owned subsidiary T-mab, this new clearance specifically covers the use of the drug in reducing severe skeletal-related complications like
Leukemia
Chronic Myeloid Leukemia
News
FDA grants fast track designation to STX-0712 in relapsed or refractory CMML
The investigational Cytotoxicity Targeting Chimera targets the CCR2 receptor, highly expressed on malignant monocytes and bone marrow blasts to selectively eliminate disease-driving cells.